Monopar Therapeutics (NASDAQ:MNPR) Earns “Buy” Rating from Chardan Capital

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “buy” rating reiterated by equities researchers at Chardan Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $60.00 price target on the stock. Chardan Capital’s price objective suggests a potential upside of 67.32% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Wall Street Zen raised shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Cantor Fitzgerald assumed coverage on shares of Monopar Therapeutics in a research note on Monday, July 7th. They issued an “overweight” rating and a $74.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Monopar Therapeutics Stock Performance

NASDAQ MNPR opened at $35.86 on Wednesday. The business’s fifty day moving average is $38.04 and its 200 day moving average is $37.87. Monopar Therapeutics has a fifty-two week low of $2.15 and a fifty-two week high of $54.30. The company has a market capitalization of $221.26 million, a PE ratio of -10.77 and a beta of 1.05.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.12. On average, sell-side analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Activity

In other news, Director Kim R. Tsuchimoto sold 8,904 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $356,160.00. Following the sale, the director directly owned 11,486 shares in the company, valued at $459,440. This represents a 43.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Chandler Robinson sold 16,800 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the transaction, the chief executive officer directly owned 73,472 shares in the company, valued at $2,938,880. The trade was a 18.61% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,504 shares of company stock worth $1,700,160 over the last ninety days. 20.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. purchased a new position in Monopar Therapeutics during the fourth quarter worth approximately $45,000. RA Capital Management L.P. purchased a new position in Monopar Therapeutics during the fourth quarter worth approximately $11,247,000. Geode Capital Management LLC raised its stake in Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after purchasing an additional 24,530 shares during the period. Janus Henderson Group PLC purchased a new position in Monopar Therapeutics during the fourth quarter worth approximately $23,435,000. Finally, Gerber LLC purchased a new position in Monopar Therapeutics during the first quarter worth approximately $204,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.